В России зарегистрирован новый препарат для терапии почечно-клеточного рака
20 сентября 2019
Фото: depositphotos.com
Выпуск:
№188, сентябрь 2019
1231 просмотров
Array
(
[0] => Array
(
[ID] => 16466
[~ID] => 16466
[NAME] => apteka.ru/search/?q=%D1%81%D1%82%D0%B5%D0%BB%D0%BB%D0%B0%D0%BD%D0%B8%D0%BD&order=products%2Cmaterials&vendor=
[~NAME] => apteka.ru/search/?q=%D1%81%D1%82%D0%B5%D0%BB%D0%BB%D0%B0%D0%BD%D0%B8%D0%BD&order=products%2Cmaterials&vendor=
[DATE_ACTIVE_FROM] => 01.09.2019 11:17:00
[~DATE_ACTIVE_FROM] => 01.09.2019 11:17:00
[IBLOCK_ID] => 12
[~IBLOCK_ID] => 12
[PREVIEW_PICTURE] => 8171
[~PREVIEW_PICTURE] => 8171
)
[PROPERTIES] => Array
(
[SWF] => Array
(
[ID] => 99
[TIMESTAMP_X] => 2018-08-19 19:34:17
[IBLOCK_ID] => 12
[NAME] => Ссылка во флеше (link1)
[ACTIVE] => Y
[SORT] => 500
[CODE] => SWF
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => S
[ROW_COUNT] => 1
[COL_COUNT] => 50
[LIST_TYPE] => L
[MULTIPLE] => N
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 0
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Ссылка во флеше (link1)
[~DEFAULT_VALUE] =>
)
[LINK] => Array
(
[ID] => 100
[TIMESTAMP_X] => 2018-08-19 19:34:17
[IBLOCK_ID] => 12
[NAME] => Ссылка (без протокола)
[ACTIVE] => Y
[SORT] => 500
[CODE] => LINK
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => S
[ROW_COUNT] => 1
[COL_COUNT] => 50
[LIST_TYPE] => L
[MULTIPLE] => N
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 0
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] => 320465417
[VALUE] => apteka.ru/search/?q=%D0%B1%D0%B5%D1%80%D0%B5%D1%88&order=products%2Cmaterials&vendor=0
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] => apteka.ru/search/?q=%D0%B1%D0%B5%D1%80%D0%B5%D1%88&order=products%2Cmaterials&vendor=0
[~DESCRIPTION] =>
[~NAME] => Ссылка (без протокола)
[~DEFAULT_VALUE] =>
)
[WEBINARS] => Array
(
[ID] => 102
[TIMESTAMP_X] => 2020-11-05 08:23:57
[IBLOCK_ID] => 12
[NAME] => Вебинары
[ACTIVE] => Y
[SORT] => 500
[CODE] => WEBINARS
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => E
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => Y
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 5
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => Y
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] => EList
[USER_TYPE_SETTINGS] => Array
(
[size] => 20
[width] => 0
[group] => Y
[multiple] => Y
)
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Вебинары
[~DEFAULT_VALUE] =>
)
[TYPES] => Array
(
[ID] => 103
[TIMESTAMP_X] => 2018-08-20 03:08:52
[IBLOCK_ID] => 12
[NAME] => Где показывать
[ACTIVE] => Y
[SORT] => 500
[CODE] => TYPES
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => L
[ROW_COUNT] => 20
[COL_COUNT] => 30
[LIST_TYPE] => C
[MULTIPLE] => Y
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 0
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => Y
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] => Array
(
[0] => 320482201
)
[VALUE] => Array
(
[0] => Страница статьи (273px)
)
[DESCRIPTION] => Array
(
[0] =>
)
[VALUE_ENUM] => Array
(
[0] => Страница статьи (273px)
)
[VALUE_XML_ID] => Array
(
[0] => ade3837e8e0b9a67adab1fec2bc57639
)
[VALUE_SORT] => Array
(
[0] => 500
)
[VALUE_ENUM_ID] => Array
(
[0] => 458
)
[~VALUE] => Array
(
[0] => Страница статьи (273px)
)
[~DESCRIPTION] => Array
(
[0] =>
)
[~NAME] => Где показывать
[~DEFAULT_VALUE] =>
)
[RUBRICS] => Array
(
[ID] => 104
[TIMESTAMP_X] => 2018-08-20 03:09:12
[IBLOCK_ID] => 12
[NAME] => Рубрики
[ACTIVE] => Y
[SORT] => 500
[CODE] => RUBRICS
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => G
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => Y
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 20
[TMP_ID] =>
[LINK_IBLOCK_ID] => 2
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => Y
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Рубрики
[~DEFAULT_VALUE] =>
)
[VIEWS] => Array
(
[ID] => 105
[TIMESTAMP_X] => 2018-08-19 23:38:24
[IBLOCK_ID] => 12
[NAME] => Показы
[ACTIVE] => Y
[SORT] => 500
[CODE] => VIEWS
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => N
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => N
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 0
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Показы
[~DEFAULT_VALUE] =>
)
[CLICKS] => Array
(
[ID] => 106
[TIMESTAMP_X] => 2018-08-19 23:38:24
[IBLOCK_ID] => 12
[NAME] => Клики
[ACTIVE] => Y
[SORT] => 500
[CODE] => CLICKS
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => N
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => N
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 0
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] =>
[USER_TYPE_SETTINGS] =>
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Клики
[~DEFAULT_VALUE] =>
)
[ARTICLE] => Array
(
[ID] => 116
[TIMESTAMP_X] => 2019-05-17 13:18:54
[IBLOCK_ID] => 12
[NAME] => Статьи
[ACTIVE] => Y
[SORT] => 500
[CODE] => ARTICLE
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => E
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => Y
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 2
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] => EList
[USER_TYPE_SETTINGS] => Array
(
[size] => 20
[width] => 0
[group] => N
[multiple] => Y
)
[HINT] =>
[PROPERTY_VALUE_ID] => Array
(
[0] => 320482202
)
[VALUE] => Array
(
[0] => 32724
)
[DESCRIPTION] => Array
(
[0] =>
)
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] => Array
(
[0] => 32724
)
[~DESCRIPTION] => Array
(
[0] =>
)
[~NAME] => Статьи
[~DEFAULT_VALUE] =>
)
[CRIB] => Array
(
[ID] => 117
[TIMESTAMP_X] => 2019-05-30 07:53:16
[IBLOCK_ID] => 12
[NAME] => Шпаргалки
[ACTIVE] => Y
[SORT] => 500
[CODE] => CRIB
[DEFAULT_VALUE] =>
[PROPERTY_TYPE] => E
[ROW_COUNT] => 1
[COL_COUNT] => 30
[LIST_TYPE] => L
[MULTIPLE] => N
[XML_ID] =>
[FILE_TYPE] =>
[MULTIPLE_CNT] => 5
[TMP_ID] =>
[LINK_IBLOCK_ID] => 3
[WITH_DESCRIPTION] => N
[SEARCHABLE] => N
[FILTRABLE] => N
[IS_REQUIRED] => N
[VERSION] => 1
[USER_TYPE] => EList
[USER_TYPE_SETTINGS] => Array
(
[size] => 20
[width] => 0
[group] => N
[multiple] => N
)
[HINT] =>
[PROPERTY_VALUE_ID] =>
[VALUE] =>
[DESCRIPTION] =>
[VALUE_ENUM] =>
[VALUE_XML_ID] =>
[VALUE_SORT] =>
[~VALUE] =>
[~DESCRIPTION] =>
[~NAME] => Шпаргалки
[~DEFAULT_VALUE] =>
)
)
[1] => Array
(
[ID] => 15705
[~ID] => 15705
[NAME] => Стелланин апрель
[~NAME] => Стелланин апрель
[DATE_ACTIVE_FROM] => 01.04.2019 13:37:00
[~DATE_ACTIVE_FROM] => 01.04.2019 13:37:00
[IBLOCK_ID] => 12
[~IBLOCK_ID] => 12
[PREVIEW_PICTURE] => 7449
[~PREVIEW_PICTURE] => 7449
)
[2] => Array
(
[ID] => 32741
[~ID] => 32741
[NAME] => Береш Май Обзор писем РЗН
[~NAME] => Береш Май Обзор писем РЗН
[DATE_ACTIVE_FROM] => 28.05.2020 08:53:00
[~DATE_ACTIVE_FROM] => 28.05.2020 08:53:00
[IBLOCK_ID] => 12
[~IBLOCK_ID] => 12
[PREVIEW_PICTURE] => 10191
[~PREVIEW_PICTURE] => 10191
)
)
В России зарегистрирован новый препарат для терапии почечно-клеточного рака
Компания Ipsen сообщает о регистрации в РФ нового онкологического препарата с действующим веществом кабозантиниб. Как следует из пресс-релиза компании, препарат предназначен для терапии почечно-клеточного рака у взрослых пациентов с промежуточным или плохим прогнозом, не получавших ранее системную терапию. Также он предназначен для пациентов после лечения таргетными препаратами против фактора роста эндотелия сосудов (Vascular endothelial growth factor, VEGF).
Кабозантиниб является тирозинкиназным ингибитором нового поколения. Принцип действия препарата заключается в одновременном ингибировании ряда рецепторных тирозинкиназ, включая три ключевых компонента опухолевой прогрессии (VEGFR, MET, AXL), что способствует преодолению резистентности к терапии и препятствует опухолевому ангиогенезу.
В клинических испытаниях прием препарата сравнивался со стандартной терапией сунитинибом у пациентов, ранее не получавших лечения почечно-клеточного рака, с промежуточным или плохим прогнозом. Исследования показали, что прием кабозантиниба позволяет достичь большей выживаемости без прогрессирования у пациентов (в среднем на 3,3 месяца больше). Также препарат показал лучший контроль над заболеванием в сравнении с сунитинибом (75 % и 47 % соответственно).
Кроме этого, были проведены исследования по сравнению приема кабозантиниба и противоопухолевого препарата эверолимус у пациентов с распространенным почечно-клеточным раком после прогрессии на антиангиогенной терапии. У этой группы пациентов кабозантиниб продемонстрировал большие показатели общей выживаемости (+4,3 месяца) и выживаемости без прогрессирования (+3,5 месяца).
Катрен Стиль
зарегистрированным пользователям